Drugs / CART20
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02965157 | Aug 2016 → Jan 2018 | B-cell non-Hodgkin lymphoma | Beijing Biohealthcare Biotechnology Co.,Ltd | Unknown | No outcome recorded |
| Phase 1/2 | NCT01735604 | Jan 2013 → May 2017 | B-cell adult acute lymphocytic leukemia, B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma, mantle cell lymphoma +1 | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CART20 | “We performed a phase IIa trial to further assess the safety and efficacy of administering autologous anti-CD20 CART (CART-20) cells to patients with refractory or relapsed...” PMID 29263894 ↗ Mar 2016 |
| Known as | anti-CD20 CART | “We performed a phase IIa trial to further assess the safety and efficacy of administering autologous anti-CD20 CART (CART-20) cells to patients with refractory or relapsed...” PMID 29263894 ↗ Mar 2016 |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) T cells targeting CD20” NCT02965157 ↗ |